Combination of Ranibizumab and Targeted Laser Photocoagulation
NCT: NCT04444492 · ACTIVE_NOT_RECRUITING
Brief Summary
Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targeted laser photocoagulation of the peripheral areas of capillary non-perfusion (up to 4 laser treatments within 1st year of the study). Based on the long-term observation after CoRaLa I study an importantly shorter duration of treatment and a relevant reduction of the total number of re-injections in RL patients is expected.
Frequently Asked Questions
What is Combination of Ranibizumab and Targeted Laser Photocoagulation?
Combination of Ranibizumab and Targeted Laser Photocoagulation is a clinical trial registered under NCT04444492. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT04444492?
The current status of NCT04444492 (Combination of Ranibizumab and Targeted Laser Photocoagulation) is: ACTIVE_NOT_RECRUITING.
When did Combination of Ranibizumab and Targeted Laser Photocoagulation start?
Combination of Ranibizumab and Targeted Laser Photocoagulation started on 2020-08-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.